中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
7期
10-11,12
,共3页
袁刚%杨通林%曾昱%叶文莉
袁剛%楊通林%曾昱%葉文莉
원강%양통림%증욱%협문리
喹硫平%利培酮%老年期痴呆
喹硫平%利培酮%老年期癡呆
규류평%리배동%노년기치태
quetiapine%risperidone%senile dementia
目的:比较喹硫平和利培酮治疗老年期痴呆精神行为症状的疗效和安全性。方法将55例老年期痴呆患者随机分为喹硫平组28例,利培酮组27例,共观察8周。治疗前及治疗后第2,4,8周分别采用阿尔茨海默病病理行为评定量表(BEHAVE - AD)评定疗效,采用不良反应量表(TESS)评定不良反应,采用简易智力状态检查(MMSE)评定认知功能。结果两组临床总有效率分别为82.14%和88.89%,无显著性差异( P ﹥0.05);2组在治疗后2周末起 BEHAVE - AD 评分有显著下降( P ﹤0.01或 P ﹤0.05),治疗结束后组间BEHAVE - AD 评分和 MMSE 评分均无显著性差异( P ﹥0.05);两组锥体外系反应发生率比较有显著性差异,喹硫平组更低( P ﹤0.01)。结论喹硫平治疗老年期痴呆精神行为障碍疗效与利培酮相当,但锥体外系反应较利培酮少,更适用于老年患者。
目的:比較喹硫平和利培酮治療老年期癡呆精神行為癥狀的療效和安全性。方法將55例老年期癡呆患者隨機分為喹硫平組28例,利培酮組27例,共觀察8週。治療前及治療後第2,4,8週分彆採用阿爾茨海默病病理行為評定量錶(BEHAVE - AD)評定療效,採用不良反應量錶(TESS)評定不良反應,採用簡易智力狀態檢查(MMSE)評定認知功能。結果兩組臨床總有效率分彆為82.14%和88.89%,無顯著性差異( P ﹥0.05);2組在治療後2週末起 BEHAVE - AD 評分有顯著下降( P ﹤0.01或 P ﹤0.05),治療結束後組間BEHAVE - AD 評分和 MMSE 評分均無顯著性差異( P ﹥0.05);兩組錐體外繫反應髮生率比較有顯著性差異,喹硫平組更低( P ﹤0.01)。結論喹硫平治療老年期癡呆精神行為障礙療效與利培酮相噹,但錐體外繫反應較利培酮少,更適用于老年患者。
목적:비교규류평화리배동치료노년기치태정신행위증상적료효화안전성。방법장55례노년기치태환자수궤분위규류평조28례,리배동조27례,공관찰8주。치료전급치료후제2,4,8주분별채용아이자해묵병병리행위평정량표(BEHAVE - AD)평정료효,채용불량반응량표(TESS)평정불량반응,채용간역지력상태검사(MMSE)평정인지공능。결과량조림상총유효솔분별위82.14%화88.89%,무현저성차이( P ﹥0.05);2조재치료후2주말기 BEHAVE - AD 평분유현저하강( P ﹤0.01혹 P ﹤0.05),치료결속후조간BEHAVE - AD 평분화 MMSE 평분균무현저성차이( P ﹥0.05);량조추체외계반응발생솔비교유현저성차이,규류평조경저( P ﹤0.01)。결론규류평치료노년기치태정신행위장애료효여리배동상당,단추체외계반응교리배동소,경괄용우노년환자。
Objective To study the efficacy and safety of quetiapine and risperidone for treating mental and behavioral symptoms in el-derly patients with dementia. Methods 55 inpatients with senile dementia were randomly assigned into two groups and treated with quetiapine(28 cases) or risperidone(27 cases) for an 8 - week treatment. The AD pathological behavior rating scale (BEHAVE - AD) and the Treatment Emergent Symptoms Scale(TESS) were used to evaluate the curative efficacy and the adverse reactions before treat-ment and at the end of 2nd, 4th, 8th week after treatment. The mini - mental state examination(MMSE) was used to evaluate the cogni-tive function. Results The total effective rates after treatment in the quetiapine group and the risperidone group were 82. 14% and 88. 89% respectively, no statistically significant difference was found between the two groups( P ﹥ 0. 05); the BEHAVE - AD scores at the end of 2nd week in the two groups began to be significantly decreased( P ﹤ 0. 01 or P ﹤ 0. 05), with no statistically significant dif-ference between the two groups; the BEHAVE - AD scores and the MMSE scores at the end of treatment had no statistically significant differences between the two groups( P ﹥ 0. 05 ); the occurrence rate of extrapyramidal symptoms(EPS) had statistically significant differ-ence between the two groups( P ﹤ 0. 01). Conclusion Quetiapine is as effective as risperidone for treating senile dementia, but has few-er extrapyramidal reactions than risperidone and would be more suitable for elderly patients.